Table 3.
Insulin Kinetics by Treatment Group
| Fasting (n = 11) | Standard meal test (n = 3) | All patients (n = 14) | ||||||
|---|---|---|---|---|---|---|---|---|
| Data | ID | SC | P | ID | SC | ID | SC | P |
| Tmax, Minutes | ||||||||
| Median | 35 | 90 | <0.001 | 50 | 70 | 35 | 87.5 | <0.001 |
| IQR | 30–40 | 60–115 | 30–60 | 50–90 | 30–40 | 60–110 | ||
| Cmax, μU/mL | ||||||||
| Median | 79 | 54.5 | 0.125 | 95 | 68 | 80 | 55 | 0.085 |
| IQR | 47–104 | 46–58 | 78–98 | 64–111 | 51–98 | 47–68 | ||
| AUC, μU/mL/min | ||||||||
| Median | 9672.5 | 10,407.5 | 0.215 | 12690 | 13960 | 9913.75 | 10936.25 | 0.077 |
| IQR | 5578–12125 | 9280–12196 | 10060–17655 | 12640–23050 | 5800–13685 | 9305–13690 | ||
Fourteen patients with diabetes received injections of aspart (Novorapid), both ID using a MicronJet needle and SC injections, in a crossover design. Eleven were in the fasting state and 3 received the injection before a standard meal test. Insulin pharmacokinetics is shown. P value was not calculated in the subjects receiving insulin poststandard meal test due to the small number of subjects.
ID, intradermal; SC, subcutaneous.
P values in boldface are statistically significant.